BD2K product for enhancing phenotypic screens

用于增强表型筛选的 BD2K 产品

基本信息

批准号：
10020785
负责人：
Jennifer Fuller
金额：
$ 72.98万
依托单位：
GENECENTRIX, INC.
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-30 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10020785
关键词：
Address Adverse event Agonist Algorithms Antipsychotic Agents Area Atlases Award Big Data Big Data to Knowledge Bioinformatics Biological Assay Biological Models Brain Buprenorphine Bupropion Businesses Cell Nucleus Cells Clinic Clinical Clozapine Clozaril Computational Biology Computer software Data Data Set Development Disease Drug Addiction Drug Antagonism Drug Industry Drug Kinetics Drug Screening Epidemic Funding Gene Expression Goals Informatics Investments Lead Licensing Market Research Mental Health Methadone Methods Modeling Molecular Molecular Computations Molecular Target Naltrexone National Institute of Drug Abuse Neurosciences Nucleus Accumbens Pattern Performance Pharmaceutical Preparations Pharmacologic Substance Pharmacology Phase Phenotype Probability Process Proteomics Psychiatry Public Health Publications Reporting Research Side Sister Specificity Spinal Ganglia Statistical Models Structure Substance abuse problem Technology Testing Time Tissues Translating Translations United States National Institutes of Health Update addiction base brain tissue cloud based commercialization computational chemistry craving data harmonization data integration design digital drug action drug candidate drug development drug discovery drug of abuse falls human tissue insight interest molecular modeling mu opioid receptors novel novel drug class novel therapeutics opioid use disorder prescription opioid prevent product development programs protein expression prototype receptor research and development screening screening program small molecule tool trend user-friendly validation studies

项目摘要

The public health problem addressed by the proposed project is the critical, long-term absence of progress in anti-addiction medication discovery and development. GeneCentrix’ “historeceptomics” technology has the potential to alter this trend by providing advanced insights during the process of anti-addiction medication discovery and development. Digital/computational advanced insights are recognized as the critical value- added emerging piece of technology in pharmaceutical R&D. The unique concept underlying our technology is specificity of anti-addiction drug action in different brain tissues. No software product currently provides this capability. The overall goal of this program is to commercialize a product that enhances anti-addiction medication discovery by providing previously unavailable advanced structure-activity insights specifically targeted to phenotypic screening assays. A Phase I award successfully established the technical merit, feasibility and commercial potential of the envisioned product, as well as identifying the key remaining concerns of customers who expressed intent to purchase the product capabilities. The overall objective of this Phase II renewal is to produce a commercialization ready software product that eliminates the remaining concerns of the customers for commercialization. Based on the prototype built in Phase I and the insights gained from market analysis, the remaining obstacles to commercialization and sustainability of the product have been identified. In this Phase II project, we will establish a partnership with a sister company in the space, Molsoft LLC, whose products already addresses a key customer concern. The GeneCentrix technology to enhance the translatability of phenotypic screens will be integrated as feature into Molsoft’s ICM product line (Aim 1). In addition, customer requested and sponsor (NIDA/NCATS)-desired R&D will update the product core to optimize it for anti-addiction drug discovery by incorporation of new and growing brain atlas, proteomic and pharmacokinetic big data (Aim 2). For this FOA, this application falls within Area 4: Tools and Model Systems for OUD Research and proposes a project including the development of drug discovery and development- enabling technologies. Funding is sought for activities and steps in the product development process encompassing the development and demonstration of the capability of bioinformatic methods or algorithms for research data integration and data harmonization. Accordingly, as required by the FOA, a broad validation study (Aim 3) will be performed of the technology that that will demonstrate and validate the commercial utility and value proposition of the proposed technology. The commercial plan establishes a clear and feasible approach to take advantage of a growing business opportunity that should lead to a sustainable product cycle with minimal further Phase III investment. Overall, a needed commercial software product could emerge from NIH product development support that could contribute to anti-addiction drug discovery.

拟议项目解决的公共卫生问题是关键的、长期缺乏进展的问题 GeneCentrix 的“historeceptomics”技术具有抗成瘾药物的发现和开发。通过在抗成瘾药物治疗过程中提供先进的见解，有可能改变这一趋势发现和开发。数字/计算先进的见解被认为是关键价值。添加了药品研发中的新兴技术我们技术背后的独特概念是。目前还没有软件产品提供不同脑组织中抗成瘾药物作用的特异性。该计划的总体目标是将增强抗成瘾性的产品商业化。通过专门提供以前无法获得的高级结构-活性见解来发现药物针对表型筛选测定的第一阶段奖项成功确立了技术优势，设想产品的可行性和商业潜力，以及确定剩余的关键表示有意购买产品功能的客户所关注的问题。第二阶段更新是生产一个商业化的软件产品，消除剩余的基于第一阶段构建的原型和见解。从市场分析中得出产品商业化和可持续性的剩余障碍已经确定，在这个第二阶段项目中，我们将与该领域的一家姐妹公司建立合作伙伴关系， Molsoft LLC 的产品已经解决了 GeneCentrix 技术的一个关键客户问题。增强表型筛选的可翻译性将作为功能集成到 Molsoft 的 ICM 产品线中（目标 1）此外，客户要求和赞助商 (NIDA/NCATS) 所需的研发将更新产品核心。通过结合新的和不断增长的大脑图谱、蛋白质组学和药代动力学大数据（目标 2）对于该 FOA，该应用属于领域 4：工具和模型系统。为 OUD Research 提出了一个项目，包括药物发现和开发- 为产品开发过程中的活动和步骤寻求资金。包括开发和展示生物信息学方法或算法的能力因此，根据 FOA 的要求，进行广泛的验证。将对该技术进行研究（目标 3），以证明和验证商业效用商业计划建立了清晰且可行的技术和价值主张。利用不断增长的商业机会的方法，从而实现可持续的产品周期总体而言，只需最少的第三阶段投资，就可以产生所需的商业软件产品。 NIH 产品开发支持可能有助于抗成瘾药物的发现。

项目成果

期刊论文数量（1）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

How polypharmacologic is each chemogenomics library?

每个化学基因组库的多药理学如何？

DOI：
10.4155/fdd-2019-0032
发表时间：
2020
期刊：
Future drug discovery
影响因子：
0
作者：
Ni,Eric;Kwon,Eehjoe;Young,LaurenM;Felsovalyi,Klara;Fuller,Jennifer;Cardozo,Timothy
通讯作者：
Cardozo,Timothy